Rice Hall James & Associates LLC Purchases New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rice Hall James & Associates LLC purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 53,375 shares of the company’s stock, valued at approximately $1,023,000.

A number of other institutional investors also recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Viridian Therapeutics during the fourth quarter worth $26,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Viridian Therapeutics by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock worth $318,000 after purchasing an additional 2,036 shares in the last quarter. AlphaCentric Advisors LLC boosted its position in Viridian Therapeutics by 20.0% during the third quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock worth $341,000 after purchasing an additional 2,500 shares in the last quarter. Principal Financial Group Inc. boosted its position in Viridian Therapeutics by 3.3% during the fourth quarter. Principal Financial Group Inc. now owns 178,444 shares of the company’s stock worth $3,421,000 after purchasing an additional 5,634 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Viridian Therapeutics during the third quarter worth $149,000.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. TD Cowen assumed coverage on Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating on the stock. Royal Bank of Canada boosted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Monday, December 16th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Finally, Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Stock Down 3.4 %

Viridian Therapeutics stock opened at $15.85 on Wednesday. The stock has a fifty day moving average price of $18.73 and a 200 day moving average price of $19.65. Viridian Therapeutics, Inc. has a 52 week low of $11.40 and a 52 week high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.